The companion piece to this article looks at a shift in my own clinical approach — when I see persistent thyroid symptoms in patients on Synthroid, I am now addressing the medication directly rather than working around it with supplements. You can read it here: Why I Started Changing My Patients' Thyroid Medication — and What Happened Next.
What follows is the clinical framework behind that shift. The biochemistry of why T4-only medication so frequently fails women in perimenopause and menopause. What desiccated thyroid does differently. And why free T3 — not TSH, not T4 — is the number that tells you whether a woman's thyroid treatment is actually working.
Key Highlights
- Synthroid is synthetic levothyroxine — a T4-only medication that is not bioidentical to the hormone the thyroid produces
- T4 is largely inactive. It must be converted to T3 to do anything useful at the cellular level — and that conversion step fails in a significant percentage of women, particularly in perimenopause and menopause
- Free T3 is the only thyroid hormone that cells can actually use. When it is functionally low — even within the standard reference range — the full picture of hypothyroid symptoms is present regardless of what TSH shows
- Desiccated thyroid (Armour Thyroid, NP Thyroid) contains both T4 and T3 in a ratio that approximates natural thyroid output, bypassing the conversion step that is failing
- Women who switch from Synthroid to desiccated thyroid — or who add T3 support — frequently see rapid and meaningful symptom resolution that years on T4-only medication never produced
- The decision to switch or adjust requires a complete thyroid panel read through an optimal lens, not just TSH monitoring
What Synthroid Is — and What It Is Not
Levothyroxine, sold under the brand name Synthroid among others, is the most prescribed medication in the United States. It is a synthetic form of T4 — thyroxine — the primary hormone the thyroid gland produces. It has been the standard pharmacological treatment for hypothyroidism since the 1960s.
Two things are important to understand about levothyroxine that are almost never explained to patients when it is prescribed.
First, it is synthetic. Levothyroxine is a chemically manufactured molecule. It is structurally identical to T4 at the molecular level, but it is not derived from biological thyroid tissue. This matters less than the second point, but it is relevant when comparing it to bioidentical and biologically derived alternatives.
Second, and more importantly, T4 is largely inactive. It is a storage and transport hormone. On its own, it does almost nothing at the cellular level. Before it can drive any of the metabolic functions we associate with thyroid health — energy production, metabolic rate, cognitive function, hair growth, temperature regulation, mood stability — it must be converted to T3, triiodothyronine, the active hormone that cells actually use.
Synthroid provides T4. It assumes the body will convert that T4 to T3. For a significant percentage of women — particularly those in perimenopause and menopause, who are simultaneously dealing with blood sugar dysregulation, gut dysfunction, chronic stress, and nutrient depletion that all impair conversion — that assumption is wrong.
These symptoms are frequently attributed entirely to estrogen — low estrogen, fluctuating estrogen, or estrogen dominance. Estrogen is genuinely part of the story for many women, and I do not dismiss it. But it is rarely the whole story. A woman can be on hormone therapy, feel some improvement, and still be exhausted, still losing hair, still carrying weight she cannot move, still waking at 3am — because the thyroid was never properly addressed. Estrogen and thyroid are connected systems, but treating one does not automatically fix the other. When the thyroid piece is missed, no amount of hormonal optimization fills the gap.
The Conversion Problem
T4 to T3 conversion is not a simple or robust process. It happens primarily in the liver and gut through the action of deiodinase enzymes, and it is sensitive to a wide range of physiological stressors.
Chronic stress and elevated cortisol suppress the deiodinase enzyme that converts T4 to active T3 while upregulating the enzyme that converts T4 to reverse T3 — an inactive form that occupies T3 receptors without activating them. The result is a system that is producing T4, has adequate T4 levels, and is generating something that looks like T3 on a basic panel while delivering very little active hormone to cells.
Blood sugar dysregulation impairs conversion directly. Insulin resistance creates a metabolic environment that slows deiodinase activity and increases reverse T3 production. Women with insulin resistance who are also on T4-only thyroid medication frequently have the conversion problem compounded by the metabolic problem, and neither is fully addressable without addressing both.
Gut dysfunction reduces T4 to T3 conversion in the gut itself, which accounts for approximately 20 percent of the body's total conversion. Dysbiosis, intestinal permeability, and chronic gut inflammation all impair this pathway. A woman with significant gut dysfunction who is on Synthroid is losing a meaningful fraction of her conversion capacity in the gut before the T4 even reaches the liver.
Nutrient depletion completes the picture. Selenium is required by all three deiodinase enzymes. Without adequate selenium, conversion slows across the board. Zinc, iron, and vitamin D all play supporting roles. Perimenopausal and menopausal women are frequently deficient in multiple nutrients simultaneously, and those deficiencies compound the conversion problem that stress, blood sugar, and gut dysfunction are already creating.
The cumulative effect is a woman who is taking her Synthroid faithfully, whose TSH is in range, whose T4 is adequate, and who is still living with fatigue, brain fog, hair loss, weight resistance, morning stiffness, poor sleep, and mood changes. She has been told her thyroid is managed. Her cells are telling a different story.
What Free T3 Actually Shows
Free T3 is the biologically active, unbound thyroid hormone circulating in the bloodstream and available to enter cells. It is the only thyroid hormone that cells can actually use. It is almost never included in standard thyroid monitoring.
When I run a complete thyroid panel on a woman who is on Synthroid and still symptomatic, the pattern I see consistently is this: TSH normal, T4 normal or adequate, free T3 at the low end of the reference range or below it. Sometimes reverse T3 is elevated, competing with the T3 that is present for the same receptors.
The reference range for free T3 on a standard lab panel is broad enough that a value can fall within it while being functionally insufficient for optimal cellular activity. The bottom third of the reference range is not the same as the upper third in terms of how a woman feels and functions. Reading free T3 through an optimal lens — not just flagging it if it falls outside the reference range — changes the clinical picture entirely for many of these patients.
A woman with a free T3 at the low end of normal, a TSH of 1.8, and ten active thyroid symptoms is not a woman whose thyroid is well-managed. She is a woman whose T4 is being provided and not converted. Increasing her Synthroid dose gives her more T4 to not convert. It does not fix the free T3 problem. Only addressing the conversion — or bypassing it — does that.
What Desiccated Thyroid Is and Why It Is Different
Desiccated thyroid — sold under brand names including Armour Thyroid and NP Thyroid — is derived from porcine (pig) thyroid glands that have been desiccated and standardized. Unlike Synthroid, it is not synthetic. And unlike Synthroid, it contains both T4 and T3.
The ratio of T4 to T3 in desiccated thyroid approximates the ratio found in human thyroid output — roughly four parts T4 to one part T3. This means that when a patient takes desiccated thyroid, she is receiving active T3 directly, not waiting for a conversion step that may be failing. The T3 is present in the medication itself, bypassing the liver, gut, and deiodinase enzyme pathway entirely.
For women whose conversion is impaired by any of the factors described above — stress, blood sugar dysregulation, gut dysfunction, nutrient depletion — this is a clinically significant difference. You are no longer asking a system that is not converting well to produce the hormone it is struggling to make. You are delivering it.
Desiccated thyroid is not a new therapy. It predates Synthroid by decades and was the standard treatment for hypothyroidism for most of the twentieth century before synthetic T4 became dominant in the 1960s and 70s. It has a long safety record and is FDA-approved. What changed was not the evidence base for desiccated thyroid but the ease of standardization and monitoring that synthetic T4 offered — which aligned well with a medical culture increasingly organized around single-marker management.
Why Perimenopause and Menopause Make This Problem Worse
The conversion problem that makes T4-only medication insufficient is not unique to perimenopause, but perimenopause and menopause make it significantly worse. Several things happen during the hormonal transition that directly compound T4 to T3 conversion impairment.
Cortisol dysregulation increases. The HPA axis becomes less well-regulated during perimenopause as the sex hormone environment shifts, and cortisol patterns that were previously stable become more erratic. Elevated cortisol is one of the most potent suppressors of T4 to T3 conversion, because it upregulates the enzyme that produces reverse T3 at the expense of the enzyme that produces active T3. A woman who had adequate conversion on Synthroid in her 30s may find that the cortisol dysregulation of perimenopause tips her over into significant conversion impairment in her 40s and 50s.
Insulin sensitivity declines with falling estrogen. Blood sugar instability increases. And blood sugar dysregulation is a direct impairment to T4 to T3 conversion — it slows deiodinase activity and drives reverse T3 production. The same Synthroid dose that was working adequately before the metabolic shift of perimenopause may no longer provide sufficient active T3 once insulin resistance begins to develop.
Gut microbiome changes occur during perimenopause and menopause that can further reduce the 20 percent of T4 to T3 conversion that happens in the gut. The estrobolome — the collection of gut bacteria responsible for estrogen metabolism — shifts as estrogen declines, and the broader microbiome changes that accompany this affect multiple metabolic pathways including thyroid hormone conversion.
The net effect is that many women who were adequately managed on Synthroid for years find that their thyroid symptoms return or worsen as they move through perimenopause and into menopause — not because their thyroid has gotten worse, but because the conversion system that was doing the work is now failing under the compounded pressure of cortisol dysregulation, blood sugar instability, and gut changes. Their medication has not changed. Their body's ability to use it has.
For these women, the answer is rarely more T4. It is a medication that delivers what the body is no longer converting on its own.
What the Transition Looks Like in Practice
Switching from Synthroid to desiccated thyroid, or adding T3 support to an existing T4 regimen, is not a one-size-fits-all prescription. The specific approach — switch entirely, add low-dose T3, or adjust dose — depends on the complete panel picture, the patient's symptom burden, what else is going on systemically, and how long the conversion problem has been present.
What I look for before recommending a medication change is a pattern: a meaningful number of persistent thyroid symptoms in someone whose TSH and T4 are managed but whose free T3 is functionally low and whose symptom picture has not shifted sufficiently despite addressing conversion factors through nutrition and lifestyle. When that pattern is present, addressing the medication is the most direct path to the T3 the patient's cells need.
The transition requires careful dose equivalency — desiccated thyroid is dosed in grains, not micrograms, and the conversion is not linear. It requires monitoring at appropriate intervals, particularly in the early weeks of transition. And it requires ongoing attention to the complete panel rather than just TSH, because TSH behavior on desiccated thyroid is different from TSH behavior on T4-only medication.
What patients frequently report after making this change, often within the first few weeks: more energy, reduced hair loss, better sleep, less morning stiffness, improved mood, and a metabolic shift that makes weight management possible in a way it was not before. These are not placebo effects. They are the predictable result of cells that were functionally hypothyroid finally receiving the active hormone they need.
Weight deserves specific attention here. Weight resistance in perimenopause and menopause is one of the most common and most frustrating complaints I hear. There are many pieces to that puzzle — blood sugar, sleep, cortisol, gut health, sex hormones. But adequate cellular T3 is frequently the missing link that prevents any of the other pieces from working. Without sufficient T3, the metabolic machinery does not respond. Women can eat well, exercise consistently, optimize their estrogen and progesterone, and still not move the needle — because the thyroid was never truly addressed. When the T3 deficit is corrected, the other interventions finally have something to work with. It is not the only factor, but it is often the one that unlocks everything else.
Why This Matters Beyond the Thyroid
The thyroid does not operate in isolation. Every system in the body depends on adequate cellular T3 to function optimally — the cardiovascular system, the brain, the gut, the immune system, bone metabolism, and sex hormone balance. When cellular T3 is chronically insufficient, the downstream consequences touch all of these systems.
Cholesterol rises because the liver depends on T3 to clear LDL effectively. Cardiovascular risk increases. Cognitive function slows. Bone remodeling is impaired. The gut motility that depends on thyroid hormone slows, contributing to constipation and worsening the gut dysfunction that is already impairing conversion. The cycle reinforces itself.
Addressing the T3 deficit — whether through supporting conversion or through medication that delivers T3 directly — has benefits that extend well beyond the thyroid symptom list. It is one of the most leveraged interventions available in perimenopausal and menopausal women's health, precisely because it touches so many downstream systems simultaneously.
For women who have been told for years that their thyroid is managed, this is often the missing piece that explains why everything else is harder than it should be.
To learn more about how we approach thyroid health at Wellness Architecture, visit the thyroid health page.
If you are on thyroid medication and still symptomatic, the thyroid symptom assessment is a useful starting point. It captures the full symptom picture and gives you a personalized analysis of whether what you are experiencing fits the pattern of inadequate T3 support.
Take the thyroid symptom assessment here. A personalized analysis comes back to your inbox.
If you are in Menlo Park, Palo Alto, Atherton, Los Altos, Woodside, Portola Valley, Redwood City, or anywhere on the San Francisco Peninsula and you are ready to look at the full picture, schedule a free Discovery Call or book the Discovery Experience.
Want to go deeper on thyroid health? Watch these short videos:
- Understanding Thyroid Health: 9 Essential Tests You Need To Know
- The Four Key Factors You Need To Know To Understand Your Thyroid Hormone Results
- The 3 Surprising Conditions That Mimic Hypothyroidism Even With Normal Lab Results
Frequently Asked Questions
Is Synthroid ever the right medication?
Yes. For women whose conversion is intact and who respond well to T4-only medication — whose free T3 is optimal and whose symptoms resolve on Synthroid — there is no reason to change. The issue is not that Synthroid is a bad medication. It is that it is prescribed as a universal solution for a problem that is frequently more complex than it addresses. For women with significant conversion impairment, a T4-only medication is the wrong tool for the job.
Why do most doctors only prescribe Synthroid?
Synthroid became the dominant thyroid medication in the 1960s and 70s as synthetic pharmaceuticals gained preference over biological preparations. Professional society guidelines were built around TSH monitoring, which aligns well with T4-only management. Desiccated thyroid fell out of mainstream favor not because it was less effective but because it was harder to standardize and did not fit the single-marker monitoring model. Many physicians are unfamiliar with full thyroid panel interpretation and therefore do not recognize the clinical picture that calls for a different approach.
What is the difference between Armour Thyroid and NP Thyroid?
Both are desiccated porcine thyroid preparations containing T4 and T3. They have the same active ingredient but different inactive ingredients and different manufacturers. Some patients tolerate one better than the other. NP Thyroid has been reformulated in recent years, which has affected some patients' response. The choice between them is individualized based on patient response and tolerability.
Can I take desiccated thyroid if I have Hashimoto's?
Yes, in most cases. Desiccated thyroid is appropriate for Hashimoto's patients, though the autoimmune component requires its own attention — replacing thyroid hormone does not stop the immune attack on thyroid tissue. Some patients with Hashimoto's react to the porcine protein in desiccated thyroid, though this is not common. The full clinical picture, including antibody levels and immune burden, informs the approach.
How long does it take to feel different after switching?
Many patients notice changes within the first two to four weeks. Energy is often the first thing to shift, followed by sleep and morning stiffness. Hair loss typically takes longer to show improvement because the hair growth cycle is slow. Full stabilization on the new medication usually takes two to three months, after which a follow-up panel guides any dose adjustments.
Related reading:
- Your Thyroid Is Not Fine Just Because Your TSH Is Normal
- Your Hoarse Voice, Your Ear Wax, and Your Cholesterol Might Be Your Thyroid
- Is It Your Thyroid, Your Hormones, or Your Blood Sugar?
- What a Complete Lab Panel Reveals That 30 Years of Doctor Visits Missed
For further reading on thyroid hormone medications and clinical guidelines, the American Thyroid Association provides reliable patient-facing resources.